Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT04934683

The GUARDIAN Trial - Induction Agent Sub-Study

This is a sub-study of the overall GUARDIAN trial (NCT04884802) in which some GUARDIAN trial participants will be additionally randomized to etomidate vs propofol for anesthetic induction.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Conditions

Age range

45 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Shanghai Ninth People's Hospital, Shanghai, Shanghai Municipality, China

Loading trial locations.

About this study

Participants in the underlying GUARDIAN trial (NCT04884802) will be randomized to: 1) routine intraoperative blood pressure management (routine pressure management); or 2) norepinephrine or phenylephrine infusion to maintain intraoperative MAP ≥85 mmHg (tight pressure management). Participants in this sub-study will be additionally randomized to etomidate or propofol for induction of anesthesia.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • At least 45 years old;
  • Scheduled for major noncardiac surgery expected to last at least 2 hours;
  • Having general anesthesia, neuraxial anesthesia, or the combination;
  • Expected to require at least overnight hospitalization (planned ICU admission is acceptable);
  • Are designated ASA physical status 2-4 (ranging from mild systemic disease through severe systemic disease that is a constant threat to life);
  • Expected to have direct intraoperative blood pressure monitoring with an arterial catheter;
  • Cared for by clinicians willing to follow the GUARDIAN protocol;
  • Subject to at least one of the following risk factors:
  • Age >65 years;
  • History of peripheral arterial disease;
  • History of coronary artery disease;
  • History of stroke or transient ischemic attack;
  • Serum creatinine >175 μmol/L (>2.0 mg/dl) within 6 months;
  • Diabetes requiring medication;
  • Current smoking or 15 pack-year history of smoking tobacco;
  • Scheduled for major vascular surgery;
  • Body mass index ≥35 kg/m2;
  • Preoperative high-sensitivity troponin T >14 ng/L or troponin I equivalent, defined as ≥15 ng/L (Abbott assay), 19 ng/L (Siemens assay, [Borges, unpublished]), or 25% of the 99% percentile for other assays - all within 6 months;
  • B-type natriuretic protein (BNP) >80 ng/L or N-terminal B-type natriuretic protein (NTProBNP) >200 ng/L within six months.

Exclusion criteria

  • Are scheduled for carotid artery surgery;
  • Are scheduled for intracranial surgery;
  • Are scheduled for partial or complete nephrectomy;
  • Are scheduled for pheochromocytoma surgery;
  • Are scheduled for liver or kidney transplantation;
  • Require preoperative intravenous vasoactive medications;
  • Have a condition that precludes routine or tight blood pressure management such as surgeon request for relative hypotension;
  • Require beach-chair positioning;
  • Have a documented history of dementia;
  • Have language, vision, or hearing impairments that may compromise cognitive assessments;
  • Have contraindications to norepinephrine or phenylephrine per clinician judgement;
  • Have previously participated in the GUARDIAN trial.

Treatment and study plan

Routine Blood Pressure Management

Procedure

Routine blood pressure control.

Tight Blood Pressure Management

Procedure

Tight blood pressure control.

Etomidate Induction

Drug

Anesthetic induction with etomidate.

Propofol Induction

Drug

Anesthetic induction with propofol.

Primary outcomes

  1. Number of Participants with a Composite of Major Perfusion-Related Complications

    Time frame: During the initial 30 days after major non-cardiac surgery

    The primary outcome is a composite of major perfusion-related complications (myocardial injury, stroke, non-fatal cardiac arrest, Stage 2-3 acute kidney injury, deep or organ-space infection, sepsis, and death) in the 30 days after major non-cardiac surgery.

Secondary outcomes

  1. Number of Participants with Postoperative Delirium

    Time frame: During the initial 4 postoperative days

    The Postoperative Delirium Three-dimensional Confusion Assessment Method (3D CAM) will be used to assess for the presence of delirium over the initial four postoperative days.

Sponsors and collaborators

Lead sponsor

The University of Texas Health Science Center, Houston

Other

Registry information

Official study title

Tight Perioperative Blood Pressure Management to Reduce Serious Cardiovascular, Renal, and Cognitive Complications: The GUARDIAN Trial (Induction Agent Sub-Study Comparing Etomidate and Propofol)

Important dates

Study start
2021
Primary completion
2026
Study completion
2027
First posted
Jun 22, 2021
Registry last updated
Aug 29, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.